Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 50 Days Payable is 1,399.74 as of Mar. 2026, which is 29% above its 10-year median of 1,085.34. GuruFocus rates BOM:540729 with a GF Score™ of 50/100 and a GF Value™ of ₹11.97 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Vanta Bioscience ranks worse than 526315.26% on this metric.
The historical rank and industry rank for Vanta Bioscience's Days Payable or its related term are showing as below:
During the past 10 years, Vanta Bioscience's highest Days Payable was 2086.72. The lowest was 85.99. And the median was 1085.34.
BOM:540729's Days Payable is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 64.64 * Ranked among companies with meaningful Days Payable only.
Vanta Bioscience's Days Payable
increased
from Mar. 2025 (377.42) to Mar. 2026 (1,399.74).
It may suggest that Vanta Biosciencedelayed paying its suppliers.
Vanta Bioscience Days Payable Related Terms
Vanta Bioscience Days Payable Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vanta Bioscience's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a Days Payable of 1,399.74 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vanta Bioscience and its competitors. This is 29% above median its historical median of 1,085.34. Over the past decade, Vanta Bioscience's Days Payable has ranged from 85.99 to 2,086.72. According to the industry distribution chart, Vanta Bioscience ranks #999999 out of 190 companies in the Medical Diagnostics & Research industry.
Is Vanta Bioscience's Days Payable too high?
Vanta Bioscience's current Days Payable of 1,399.74 is 29% above median its 10-year median of 1,085.34. Over the past 10 years, this metric has ranged from a low of 85.99 to a high of 2,086.72. The Medical Diagnostics & Research industry median Days Payable is 64.64. Vanta Bioscience's value of 1,399.74 is 2065.4% above this industry median. Based on the distribution chart, Vanta Bioscience ranks #999999 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #999999 out of 190 companies for Days Payable. This places Vanta Bioscience in the lower half of its industry. The industry median Days Payable is 64.64. Vanta Bioscience's value of 1,399.74 is 2065.4% above this benchmark. Historically, Vanta Bioscience's own Days Payable has ranged from 85.99 to 2,086.72 over the past decade. While the company's 10-year median is 1,085.34 vs. the industry median of 64.64, Vanta Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanta Bioscience's current Days Payable of 1,399.74 is 2065.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current Days Payable is 1,399.74, which is 29% above median its own 10-year median of 1,085.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.97, compared to a current price of ₹25.29 — trading 111.3% above its estimated fair value. The current Days Payable is 1,399.74, which is 29% above median its 10-year median of 1,085.34 and 2065.4% above the Medical Diagnostics & Research industry median of 64.64. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Days Payable is 1,399.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 111.3% above its estimated GF Value™ of ₹11.97.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Days Payable: 1,399.74 (29% above median its 10-year median of 1,085.34)
GF Value™: ₹11.97 vs. price of ₹25.29 (111.3% above fair value)
Industry Position: 2065.4% above the Medical Diagnostics & Research median (#999999 of 190)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score
Get the complete analysis for BOM:540729
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
